NASDAQ:VAXX Vaxxinity (VAXX) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free VAXX Stock Alerts $0.72 +0.03 (+4.36%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.67▼$0.7350-Day Range$0.62▼$0.8652-Week Range$0.56▼$3.10Volume338,465 shsAverage Volume520,400 shsMarket Capitalization$90.94 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Vaxxinity alerts: Email Address Vaxxinity MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside875.6% Upside$7.00 Price TargetShort InterestBearish8.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.11Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.42) to ($0.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.80 out of 5 starsMedical Sector473rd out of 939 stocksPharmaceutical Preparations Industry228th out of 441 stocks 3.5 Analyst's Opinion Consensus RatingVaxxinity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Vaxxinity has a forecasted upside of 875.6% from its current price of $0.72.Amount of Analyst CoverageVaxxinity has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.50% of the float of Vaxxinity has been sold short.Short Interest Ratio / Days to CoverVaxxinity has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Vaxxinity has recently increased by 5.48%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVaxxinity does not currently pay a dividend.Dividend GrowthVaxxinity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VAXX. Previous Next 4.0 News and Social Media Coverage News SentimentVaxxinity has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Vaxxinity this week, compared to 0 articles on an average week.Search Interest17 people have searched for VAXX on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.MarketBeat Follows6 people have added Vaxxinity to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxxinity insiders have not sold or bought any company stock.Percentage Held by Insiders59.07% of the stock of Vaxxinity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.95% of the stock of Vaxxinity is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vaxxinity are expected to grow in the coming year, from ($0.42) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxxinity is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxxinity is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxxinity has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Vaxxinity Stock (NASDAQ:VAXX)Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.Read More VAXX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VAXX Stock News HeadlinesMarch 28, 2024 | globenewswire.comVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual MeetingMarch 27, 2024 | investorplace.comVAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023March 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 27, 2024 | globenewswire.comVaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdatesMarch 19, 2024 | americanbankingnews.comVaxxinity (NASDAQ:VAXX) Shares Down 4.5% March 7, 2024 | globenewswire.comVaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024February 15, 2024 | finance.yahoo.comVaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol LevelsFebruary 15, 2024 | finance.yahoo.comVaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 15, 2024 | globenewswire.comVaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 13, 2024 | finance.yahoo.comVaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024January 30, 2024 | finance.yahoo.comVaxxinity, UF Join Forces Against Neurodegenerative DiseasesJanuary 30, 2024 | finance.yahoo.comVaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of FloridaJanuary 19, 2024 | finance.yahoo.comVaxxinity & UCF to Collaborate on Space Medicine ResearchJanuary 18, 2024 | finance.yahoo.comVaxxinity Announces Collaboration on Space Medicine Research with University of Central FloridaJanuary 3, 2024 | finance.yahoo.comVaxxinity to Present at the 2024 J.P. Morgan Healthcare ConferenceDecember 12, 2023 | finance.yahoo.comThe Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and VaxxinityNovember 21, 2023 | markets.businessinsider.comAlzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And OthersNovember 20, 2023 | foxnews.comSeveral Alzheimer's vaccines enter clinical trials amid breakthrough treatments' successNovember 20, 2023 | msn.comResearchers return to Alzheimer's vaccines, buoyed by recent drug successNovember 13, 2023 | finance.yahoo.comVaxxinity to Present at Upcoming November Medical and Investor ConferencesNovember 8, 2023 | finance.yahoo.comVaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 10, 2023 | finance.yahoo.comPrivate companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap declineSeptember 7, 2023 | finance.yahoo.comDown -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX)August 11, 2023 | finance.yahoo.comVaxxinity Says UB-311 Shows Potential Advancements in Alzheimer’s TreatmentAugust 10, 2023 | finance.yahoo.comVaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s DiseaseAugust 9, 2023 | finance.yahoo.comVaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive VAXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2023Today3/29/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VAXX CUSIPN/A CIK1851657 Webwww.vaxxinity.com Phone254-244-5739FaxN/AEmployees87Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+875.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-162.90% Return on Assets-79.68% Debt Debt-to-Equity Ratio0.51 Current Ratio2.15 Quick Ratio2.15 Sales & Book Value Annual Sales$70,000.00 Price / Sales1,299.14 Cash FlowN/A Price / Cash FlowN/A Book Value$0.49 per share Price / Book1.46Miscellaneous Outstanding Shares126,745,000Free Float51,877,000Market Cap$90.94 million OptionableNot Optionable Beta2.45 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Louis Garfield Reese IV (Age 42)Co-Founder & Executive Chairman of the Board Comp: $83.28kMs. Mei Mei Hu J.D. (Age 41)CEO & Director Comp: $551.73kDr. Peter Powchik M.D. (Age 67)Executive VP, Global Scientific Director and Director Mr. Jason Pesile CPA (Age 51)M.B.A., Senior Vice President of Finance & Accounting Ms. Sumita Ray J.D. (Age 50)Chief Legal & Administrative Officer Mr. Jon HarrisonChief Government OfficerMr. Mark Joinnides MSEChief of StaffMs. Amy B. Fix M.B.A.M.S., R.A.C., Chief Regulatory OfficerDr. Jean-Cosme Dodart Ph.D.Senior Vice President of ResearchMr. Dario Mirski M.D.Senior Vice President of Neuro / Chronic DiseasesMore ExecutivesKey CompetitorsTempest TherapeuticsNASDAQ:TPSTCue BiopharmaNASDAQ:CUEAclaris TherapeuticsNASDAQ:ACRSVeruNASDAQ:VERURezoluteNASDAQ:RZLTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 13,451 shares on 3/11/2024Ownership: 1.886%Bridgeway Capital Management LLCBought 154,700 shares on 2/15/2024Ownership: 0.181%Citadel Advisors LLCBought 79,444 shares on 2/15/2024Ownership: 0.063%Barclays PLCBought 50,698 shares on 2/15/2024Ownership: 0.046%Pathstone Holdings LLCBought 153,846 shares on 2/14/2024Ownership: 0.121%View All Insider TransactionsView All Institutional Transactions VAXX Stock Analysis - Frequently Asked Questions Should I buy or sell Vaxxinity stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxxinity in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VAXX shares. View VAXX analyst ratings or view top-rated stocks. What is Vaxxinity's stock price target for 2024? 1 Wall Street analysts have issued 12-month price objectives for Vaxxinity's shares. Their VAXX share price targets range from $7.00 to $7.00. On average, they predict the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 875.6% from the stock's current price. View analysts price targets for VAXX or view top-rated stocks among Wall Street analysts. How have VAXX shares performed in 2024? Vaxxinity's stock was trading at $0.85 on January 1st, 2024. Since then, VAXX shares have decreased by 15.6% and is now trading at $0.7175. View the best growth stocks for 2024 here. When is Vaxxinity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our VAXX earnings forecast. How were Vaxxinity's earnings last quarter? Vaxxinity, Inc. (NASDAQ:VAXX) released its quarterly earnings data on Monday, March, 27th. The company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). What ETF holds Vaxxinity's stock? Amplify Treatments, Testing and Advancements ETF holds 35,725 shares of VAXX stock, representing 0.58% of its portfolio. When did Vaxxinity IPO? Vaxxinity (VAXX) raised $90 million in an IPO on Thursday, November 11th 2021. The company issued 6,000,000 shares at $14.00-$16.00 per share. Who are Vaxxinity's major shareholders? Vaxxinity's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (1.89%), Northern Trust Corp (0.26%), Bridgeway Capital Management LLC (0.18%), Pathstone Holdings LLC (0.12%), Ieq Capital LLC (0.07%) and Citadel Advisors LLC (0.06%). Insiders that own company stock include Lou Reese, Mei Mei Hu, Movers Lab Fund I Lp Prime and United Biomedical Inc. View institutional ownership trends. How do I buy shares of Vaxxinity? Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VAXX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.